Office of Technology Transfer
and Development
Cultiviating Tomorrow's Technology Today
From the Director, NHLBI Elizabeth G. Nabel,
M.D.
The National Heart, Lung, and Blood Institute
(NHLBI) views technology transfer as a unique opportunity to expedite the
transfer of research results to improve public health while simultaneously
establishing collaborative relationships with industry. Federal legislation,
including the Federal Technology Transfer Act of 1986 and the subsequent
National Technology Transfer Advancement Act of 1996, empowers the Institute to
interact directly with industry to translate our research results into
commercial products that benefit public health.
The NHLBI has seized this opportunity, offering its
leading edge technology to industry for further development and
commercialization. The research of the Institute's 300 tenured doctoral level
scientists and post doctoral fellows has resulted in the development of many
innovative heart, lung and blood-related technologies. Scientific areas of
expertise include: molecular immunology, genetic therapy, biochemical genetics,
cell biology and metabolism, magnetic resonance imaging, and clinical research
(e.g., hypertrophic cardiomyopathy, bone marrow transplantation). By matching
our promising technologies with appropriate industrial partners, we are now
able to transfer research results more efficiently from the bench to the
bedside for the benefit of the nation's health. The NHLBI Office of Technology
Transfer and Development (OTTAD) is responsible for the implementation of
Cooperative Research and Development Agreements (CRADAs), Clinical Trial
Agreements, Material Transfer Agreements (MTAs), and licensing arrangements.
For more information on establishing collaborative research agreements or
pursuing licensing opportunities, please contact
OTTAD.
|